Nama's AI scorecard currently rates Trulieve Cannabis Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is TRLV's P/E ratio?

Trulieve Cannabis trades at a trailing price-to-earnings ratio of 41.3.

When does TRLV report earnings?

Trulieve Cannabis's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.12.

What is the TRLV price target?

The median analyst price target from 7 analysts is $19.00, with a range of $15.00 – $21.00.

Is TRLV Shariah compliant?

Nama's AAOIFI-style screen reads Trulieve Cannabis as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Trulieve Cannabis (TRLV)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Trulieve Cannabis (TRLV) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $2.23B, a trailing price-to-earnings ratio of 41.3 and a free-cash-flow yield of 9.6%. Over the most recent reported fiscal year, revenue declined 0.5% and free cash flow per share grew 70.3%. Nama's AI scorecard rates it Buy, 6.3 out of 10.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-10.6%

How far the last close sits under the highest price of the past five years.

Market cap	$2.23B
Trailing P/E	41.3
Price / book	2.9
Price / sales	1.9
FCF yield	9.6%
Dividend yield	—
Gross margin	59.5%
Operating margin	11.5%
Net margin	-41.5%
Revenue growth (YoY)	-0.5%
Revenue growth (3-yr annual)	-1.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	+70.3%
Beta	1.8
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

TRLV earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.12). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.09	$0.07	+28.6%	—
Q2 2026	Aug 7, 2026	$0.11	$0.03	+266.7%	$270.95M
Q1 2026	May 7, 2026	$0.10	-$0.05	+300.0%	$286.75M
Q4 2025	Feb 26, 2026	-$0.02	-$0.03	+33.3%	$293.15M

TRLV analyst price target

Median target $19.00 from 7 analysts, ranging $15.00 – $21.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live TRLV data on Nama Insights →

TRLV FAQ

Is TRLV a buy?: Nama's AI scorecard currently rates Trulieve Cannabis Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TRLV's P/E ratio?: Trulieve Cannabis trades at a trailing price-to-earnings ratio of 41.3.
When does TRLV report earnings?: Trulieve Cannabis's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.12.
What is the TRLV price target?: The median analyst price target from 7 analysts is $19.00, with a range of $15.00 – $21.00.
Is TRLV Shariah compliant?: Nama's AAOIFI-style screen reads Trulieve Cannabis as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.